Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07231757 · ClinicalTrials.gov registry record
The RADIANCE CED Study
A clinical trial of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT07231757: Recruiting study of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.
NCT07231757 is a study of Hypertension and Cardiovascular Diseases that is actively recruiting participants, run by ReCor Medical. The registered enrollment target is 1,000 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07231757, a study of Hypertension and Cardiovascular Diseases, is actively recruiting participants, sponsored by ReCor Medical.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The RADIANCE CED study is a prospective observational study designed to evaluate the long-term effectiveness of ultrasound renal denervation in lowering blood pressure among patients with uncontrolled hypertension. Data will be collected from electronic health records (EHRs) of Medicare-eligible patients to support generalizability of outcomes to the broader Medicare population. Individual hospital enrollment is not required for this study and IRB exemption has been received by sponsor.
Conditions Studied
Interventions
- DEVICE Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System)
Study Locations (1)
Michigan
- Henry Ford St. John Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2031-12-31 |
What NCT07231757 shows while recruiting
NCT07231757 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System) is the first listed.
NCT07231757 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07231757 about?
NCT07231757 is a clinical study titled "The RADIANCE CED Study". The RADIANCE CED study is a prospective observational study designed to evaluate the long-term effectiveness of ultrasound renal denervation in lowering blood pressure among patients with uncontrolled hypertension. Data will be collected from electronic health records (EHRs) of Medicare-eligible pat...
What is the current status of trial NCT07231757?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-11-21. Estimated completion is 2031-12-31.
What conditions does trial NCT07231757 study?
This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases.
What interventions are being tested in trial NCT07231757?
The interventions under investigation include: Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System) (DEVICE).
Who is sponsoring clinical trial NCT07231757?
This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07231757 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07231757's enrollment target sits among peer trials
1,000 65th of 470 higher than 396 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women
RECRUITING
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI